CV Therapeutics-Gilead Sciences deal sparks lawsuit
The $1.4 billion deal that Foster-City based Gilead Science's announced March 12 to buy CV Therapeutics of Palo Alto has triggered a class-action shareholder lawsuit.
The legal action, which CV Therapeutics disclosed today in a filing with the U.S. Securities and Read More →
Louis Lange, the chief executive of CV Therapeutics, agreed in effect to sell his entire stake in the company to Gilead Sciences as an "inducement" to that company to enter into 
